- Home
- HOTH
as 08-01-2025 4:00pm EST
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 15.6M | IPO Year: | 2019 |
| Target Price: | $4.00 | AVG Volume (30 days): | 421.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.58 - $3.80 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Hoth Therapeutics Inc. News
HOTH Breaking Stock News: Dive into HOTH Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment
TipRanks
a month ago
Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study
GlobeNewswire
a month ago
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
PR Newswire
a month ago
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
MT Newswires
a month ago
Sector Update: Health Care Stocks Higher in Afternoon Trading
PR Newswire
a month ago
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
PR Newswire
a month ago
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
MT Newswires
a month ago
Hoth Therapeutics Regains Nasdaq Compliance
Compare HOTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOTH Hoth Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.